Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
BOSTON - Tristel plc (AIM:TSTL) exhibited at the Association for Professionals in Infection Control and Epidemiology (APIC) 2025 conference, where it launched Tristel OPH, a high-level disinfectant for ophthalmic instruments recently cleared by the U.S. Food and Drug Administration.
The company showcased its new product at the annual infection prevention conference, which is considered the largest such event in the United States. According to a company press release, the disinfectant addresses infection control needs in ophthalmology while improving clinical workflow efficiency.
Tristel also displayed its FDA-cleared Tristel ULT disinfectant for ultrasound probes at the conference. The product is distributed by Parker Laboratories, Inc. Additionally, the company presented Tristel 3T, its digital traceability platform.
The company stated that the new ophthalmic disinfectant generated significant interest from infection prevention professionals at the event, with many health systems engaging directly with Tristel representatives for demonstrations and discussions about product evaluation.
Stock of Tristel OPH is expected to be available in August 2025, with the company currently supporting U.S. institutions in preparation for clinical trials and internal validation.
Tristel is a manufacturer of infection prevention products listed on London’s AIM market. The company described its participation at APIC 2025 as reinforcing its growing presence in the U.S. market for medical device disinfection solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.